Maze Therapeutics, Inc. Common Stock
Veridion Score
Composite trend over time
Why is MAZE moving today?
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for MAZE.
MAZE insider activity
Maze Therapeutics, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for MAZE.
MAZE contract awards, year to date.
Public federal awards linked to this ticker.
MAZE lobbying filings, year to date.
Registered lobbying filings matched to Maze Therapeutics, Inc. Common Stock.